Compare Lumen Technologies Inc (LUMN) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs Viatris Inc — how do they compare? Lumen Technologies Inc trades at $5.3 (market cap $5.73B), while Viatris Inc trades at $17.69 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 3.5× Lumen Technologies Inc's market cap, and Viatris Inc pays a 2.75% dividend while Lumen Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lumen Technologies Inc for 40 Days and Viatris Inc for 57 Days on average.
| LUMN | VTRS | |
|---|---|---|
Market Cap | $5.73B | $20.03B |
Volume | 17,079,799 | 14,109,977 |
Sector | Media | Health |
52-Week High | $11.83 | $18.27 |
52-Week Low | $5.53 | $9.74 |
Typical Hold Time | 40 Days | 57 Days |
Enterprise Value | $17.35B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN trades at $5.20, down 12.01% in 24 hours, reflecting bearish technical signals and negative profitability. Revenue declined to $12.40B in 2025 with a net loss of $1.74B, though recent product launches like Intelligent Internet target AI-driven growth. The stock faces high debt levels at $17.49B long-term, while analyst consensus is predominantly Hold (60.71%) with a Reduce rating average.
The outlook remains challenged by legacy revenue declines and substantial debt, but strategic pivots to AI networking offer speculative upside. Key risks include persistent losses and competitive pressures, requiring careful monitoring of cash flow and execution on new initiatives for any sustained recovery.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
